ClinicalTrials.gg
Not yet recruitingNCT07920653PCE-DM2Updated Nov 5, 2026

Pilates vs. Core Stabilization for Balance and Mobility in Elderly Type 2 Diabetics

An interventional study of Pilates Training programme in Mellitus Balance Deficits Postural Balance Mobility Limitation and Type 2 Diabetes Mellitus, sponsored by Beni-Suef University. Not yet recruiting. Open to participants aged 65 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Beni-Suef University · Not applicable, Interventional, and Treatment

Updated Nov 5, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
65 Years to 75 Years
Sex
All
01

Study summary

This randomized controlled trial aims to evaluate and compare the effects of a 6-week Pilates-based rehabilitation program versus core stabilization exercises on balance deficits, postural sway, and functional mobility in elderly patients with type 2 diabetes. The study seeks to determine which intervention is more effective in improving neuromuscular control, stability, and overall functional independence in this geriatric diabetic population.

Read the detailed description

Type 2 diabetes mellitus in elderly individuals is frequently associated with peripheral neuropathy, reduced muscle strength, and balance impairment, leading to an increased risk of falls. Both Pilates and core stabilization exercises are non-pharmacological interventions used to enhance core stability, proprioception, and functional performance.

02

Conditions studied

  • Mellitus Balance Deficits Postural Balance Mobility Limitation
  • Type 2 Diabetes Mellitus

Keywords

  • Pilates Core Stabilization Elderly Accidental Falls
03

In context

Diabetes Mellitus, Type 2

9,618 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,340 are open to participants now.

This study's planned enrollment of 40 is below the median of 81 across 7,736 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Beni-Suef University is the lead sponsor of 342 studies on the registry; 119 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:Old age patients of both genders (age 65 tob75) diagnosed with Type 2 Diabetes Mellitus.Ability to walk independently with or without assistive devices.

  • Presence of mild to moderate balance deficits confirmed by clinical assessment.

Exclusion Criteria:Any history of severe neurological disorders (e.g., stroke, Parkinson's disease).

  • Uncontrolled cardiovascular conditions or severe orthopedic injuries affecting lower limbs.Visual or vestibular impairments that significantly affect balance.

Cognitive impairment or inability to follow instructions (Mini-Mental State Examination score below normal thresholds

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Group A -Pilates Training Exercise

    Participants in this group will undergo a structured Pilates exercise program

    Behavioral: Pilates Training programme

  • Active comparator
    Group B:Core Stabilization Group

    Participants in this group will undergo a structured core stability training program

    Behavioral: Pilates Training programme

Interventions

  • BehavioralPilates Training programme

    supervised Pilates session lasting for 45 minutes, performed 3 times per week for 8 weeks. It includes mat Pilates exercises focusing on alignment, breathing, and core control)

06

What researchers measure

Primary outcomes

  1. Postural Balance ABalance and Gait Speedssessment (Berg Balance Scale _Minimum Value): 0 (Maximum Value): 56 (Unit/Direction

    The Berg Balance Scale (BBS) will be used to assess dynamic and static balance deficits in elderly participants.

    Time frame: Baseline (Week 0) and Post-Intervention (Week 6)

Secondary outcomes

  1. Functional Mobility (Timed Up and Go Test)

    Functional Mobility (Timed Up and Go Test)

    Time frame: Baseline (Week 0) and Post-Intervention (Week 6)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared to maintain patient privacy and confidentiality as per institutional guidelines.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for May 2027, 6 months later.

Of 1,936 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 6 months is below that.

Counting every sponsor, half of 2,113 studies reached it within 20 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2026
First posted
Nov 5, 2026
StartEst.
Oct 29, 2026
Primary completionEst.
May 27, 2027
CompletionEst.
Jul 27, 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07920653
Responsible party
Aya Ali Elbakly Amer (Master Researcher, Beni-Suef University) — Principal investigator
First posted
Nov 5, 2026
Start date
Oct 29, 2026 (estimated)
Primary completion
May 27, 2027 (estimated)
Completion
Jul 27, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Heba Mohamed Ali, Ass. Prof.
Contact
Hebamohamed@pt.bsu.edu.eg
‪+20 10 06327885‬
Aya Ali Amer, Principal Investigator
Contact
aya.ali2011996@gmail.com
01021744210

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion